ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint747,212 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical companyBubendorfCIS Biopharma AG
CIS Biopharma AG Logo
Verified· 2 sourcesTrust Score
Summary

About the company

CIS Biopharma AG is a biotechnology company developing targeted cancer therapies. Its work includes antibody-drug conjugates, nanobody-drug conjugates and radioligand therapies, with a focus on cancers such as small cell lung cancer, brain metastases and glioblastoma.

AI-generated
Offering

Products & services

Industry:Pharmaceutical company
✓ Offered8
Cancer Therapies
Targeted cancer therapies for aggressive tumors with high medical need, in particular small cell lung cancer, glioblastoma and brain metastases; based on antibody, nanobody and radioligand approaches.
Antibody-Drug-Conjugates (ADCs)
Antibody-drug conjugates for the targeted delivery of cytotoxic payloads to tumor cells; using CD171/L1CAM as the target structure, including CBO-001 for small cell lung cancer.
Nanobody-Drug-Conjugates (NDCs)
Nanobody-drug conjugates for targeted tumor treatment, in particular against CD276/B7H3; with programs for brain metastases and glioblastoma.
Radioligand Therapies (RLTs)
Targeted cancer treatments using a ligand and a radioisotope for the selective irradiation of tumor cells; implemented in the CBO-003 program against glioblastoma.
Bioconjugation platform
Platform for the development of targeted cancer therapies with protein engineering, linker chemistry and bioconjugation; includes targeting moieties, linker technology and payloads.
Targeting Moieties
Antibodies and nanobodies for binding tumor-associated antigens such as CD171/L1CAM and CD276/B7H3 for precise drug delivery.
Linker Technology
Linker and conjugation technologies for stable coupling and targeted release of payloads, including validated and new linkers, dual-drug and site-specific conjugation.
Payloads
Payload portfolio for cancer cells, including topoisomerase I inhibitors, microtubule inhibitors such as MMAE, and radionuclides.
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.0/5

CIS Biopharma AG

Trust & reputation

ranQ Trust Score of CIS Biopharma AG: 4.0 out of 5.0

Trust Score4.0/ 5.0

High

x

Data basis 54% · As of November 2026

CIS Biopharma AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
CIS Biopharma AG scores 67.9 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.50.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.70.07%
CIS Biopharma AG scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
CIS Biopharma AG scores 25.7 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.25.74%
  • Media authority: No data point — the criterion is taken out of the weighting and does not lower the score.—4%
Qualifications+0.00

CIS Biopharma AG reaches a ranQ Trust Score of 4.0 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 54%, so the score is backed by part of the criteria. As of November 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Knowledge

No knowledge articles yet

Once CIS Biopharma AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

CIS Biopharma AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank CIS Biopharma AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of CIS Biopharma AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Hauptstrasse 159
4416 Bubendorf
Opening hours
Mon
08:00 - 18:00
Tue
08:00 - 18:00
Wed
08:00 - 18:00
Thu
08:00 - 18:00
Fri
08:00 - 18:00
Sat
Closed
Sun
Closed

At a glance

Legal form
Corporation
UID
CHE-309.097.042
Founded
2023 · 3 years
Last commercial register change
November 11, 2025
Employees
11 to 20
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    SA
    SynphaBase AG
    Pratteln
    AT
    Alentis Therapeutics AG
    Allschwil
    ST
    saverna therapeutics AG
    Biel-Benken Bl
    IA
    INOFEA AG
    Muttenz
    NB
    Nanolynx Biologics AG
    Allschwil
    CP
    Corden Pharma Fribourg AG, Zweigniederlassung Ettingen
    Ettingen
    TP
    T3 Pharmaceuticals AG
    Allschwil
    BW
    Blue Wave Therapeutics GmbH
    Allschwil